Oisin Biotechnologies
Seattle, US · Delaware corporation
Find your way into Oisin Biotechnologies
590 people in our graph share verified history with the Oisin Biotechnologies team — schools, employers, funds. One of them is your warm intro.
Akshat Goenkaunlockedknows Matthew Scholz · together at Y Combinator (overlapped)
×2knows the team · via University of Washington
×7knows the team · via Y Combinator
×2knows the team · via University of Victoria
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.
Founders & leadership
MS
EG
Eric GarciainChief Operating Officer
SH
Stephen HilbertExecutive
JL
John LewisinCSOJohn Lewis is an executive officer at Oisín Biotechnologies. His research background spans nanotechnology and imaging approaches for chronic disease, with prior focus on cancer metastasis and translating diagnostics and treatments to clinical applications.
GH
Board
DG
David GobelBoard director
DQ
Danjuma QuarlessBoard director
Reported raises · per SEC filings
Form D private placements$18.4M disclosed across 4 rounds · 2017–2024
▶$5.4MraisedJul 2024 · 36 investors · BiotechnologyRule 506(b)
▶$5.4MraisedJul 2024 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric GarciaExecutive Officer
- Matthew ScholzExecutive Officer, Director
- David GobelDirector
- Stephen HilbertExecutive Officer
- John LewisExecutive Officer
- Gary HudsonExecutive Officer, Director
- Danjuma QuarlessDirector
- Offering amount
- $17.9M
- Amount sold
- $5.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$475KraisedAug 2021 · 8 investors · OtherRule 506(b)
▶$475KraisedAug 2021 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Eric GarciaExecutive Officer
- Gary HudsonExecutive Officer, Director
- David GobelDirector
- Stephen HilbertExecutive Officer
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $475K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.5MraisedMay 2021 · 90 investors · OtherRule 506(b)
▶$9.5MraisedMay 2021 · 90 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- John LewisExecutive Officer
- Eric GarciaExecutive Officer
- Steve HilbertExecutive Officer
- Gary HudsonExecutive Officer, Director
- David GobelDirector
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $9.5M
- Amount sold
- $9.5M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedFeb 2020 · 48 investors · OtherRule 506(b)
▶$3MraisedFeb 2020 · 48 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Gary HudsonDirector
- David GobelDirector
- Matthew ScholzExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Oisin Biotechnologies went on to found or lead other companies.
Competitors · 2
by search overlapBioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Clementia13 shared keywordsIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
Companies competing with Oisin Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Oisin Biotechnologies do?
- Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.
- Who founded Oisin Biotechnologies?
- Oisin Biotechnologies was founded by Matthew Scholz.
- How much funding has Oisin Biotechnologies raised?
- Oisin Biotechnologies has disclosed $18.4M raised across 4 rounds.
- Where is Oisin Biotechnologies headquartered?
- Oisin Biotechnologies is headquartered in Seattle, US.